Kyverna Therapeutics KYTX 深 沪
等待开盘 11-08 09:30:00 美东时间
6.57
-0.520
-7.33%
华盛通- 最 高6.99
- 今 开6.93
- 成交量 47.42万股
- 最 低 6.20
- 昨 收 7.09
- 总市值 2.84亿
- 52周最高 8.4471
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 1.78
- 委 比 86.74%
- 总股本 4324.57万
- 历史最高 35.06
- 量 比 1.19
- 振 幅 11.14%
- 历史最低 1.78
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kyverna Therapeutics Secures $150 Million Loan Facility
Kyverna Therapeutics, Inc. ( ($KYTX) ) just unveiled an announcement. On Octobe...
11-03 21:29
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Kyverna Therapeutics shares are trading higher after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis.
Kyverna Therapeutics shares are trading higher after the company announced inte...
10-29 21:04
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Kyverna Therapeutics To Discuss Interim Data From KYSA-6 Phase 2 Clinical Study Evaluating KYV-101 In Generalized Myasthenia Gravis On Oct. 29
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on
10-22 20:03
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
Kyverna Therapeutics will host a conference call on October 29, 2025, to discuss interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 for generalized myasthenia gravis (gMG). The data will be presented at the AANEM Annual Meeting in San Francisco. KYV-101 is a fully human CD19 CAR T-cell therapy designed to treat B-cell-driven autoimmune diseases. The call can be accessed via webcast, with registration links provided.
10-22 12:00
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
10-09 17:58
美股牛股 | SLNH飙升近40%，公司九月比特币挖掘产量上升；TRX大涨27%
SLNH升近40%，公司九月比特币挖掘产量上升；TRX涨27%，公司第四季度黄金产量环比增长37%创纪录；Zenas大涨24%，公司与诺诚健华达成超20亿美元协议>>
10-09 19:18
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $27
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $24 to $27.
10-08 22:24
